Skip to content
Triangle logo TriangleGet started
← Ovarian Neoplasm

NCT00006227 · STUDY IN CONTEXT

Paclitaxel in Treating Patients With Ovarian Stromal Cancer

Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

The probability of complete clinical response (i.e. proportion of participants) (assessed using GOG RECIST criteria) of paclitaxel as second line chemotherapy in measurable disease patients with malignant tumors of the ovarian stroma

Eligible and evaluable

→

secondary · POSTED

Duration of progression free survival (median) (months)

Source null

→

secondary · POSTED

Duration of overall survival (median) (months)

Source null

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record
trial
release id
clinical-indications-draft-1
disease state id
ds-ovarian-neoplasm
nct id
NCT00006227
trial label
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
applicability
narrower
applicability note
Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
provenance class
registry-condition-search
discovery note
Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count
3
harms Count
1
qol Count
0
outcomes
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-ovarian-neoplasm
    nct id
    NCT00006227
    outcome key
    om-0000
    source section id
    NCT00006227-om-0000
    source outcome index
    0
    endpoint
    Probability of Complete Clinical Response
    endpoint definition
    The probability of complete clinical response (i.e. proportion of participants) (assessed using GOG RECIST criteria) of paclitaxel as second line chemotherapy in measurable disease patients with malignant tumors of the ovarian stroma
    time origin
    Up to 5 years
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Eligible and evaluable
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-ovarian-neoplasm
    nct id
    NCT00006227
    outcome key
    om-0001
    source section id
    NCT00006227-om-0001
    source outcome index
    1
    endpoint
    Progression-free Survival
    endpoint definition
    Duration of progression free survival (median) (months)
    time origin
    The period from study entry until disease progression, death or date of last contact
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-ovarian-neoplasm
    nct id
    NCT00006227
    outcome key
    om-0002
    source section id
    NCT00006227-om-0002
    source outcome index
    2
    endpoint
    Overall Survival
    endpoint definition
    Duration of overall survival (median) (months)
    time origin
    The observed length of life from entry into the study to death or the date of last contact
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
arms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-ovarian-neoplasm
    nct id
    NCT00006227
    outcome key
    om-0000
    arm key
    OG000
    arm label
    Treatment (Paclitaxel)
    regimen
    Patients receive paclitaxel IV over 3 hours on day 1. Treatment continues every 21 days in the absence of disease progression or unacceptable toxicity. Paclitaxel: Given IV
    analyzed count
    31
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00006227-om-0000#groups/OG000
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-ovarian-neoplasm
    nct id
    NCT00006227
    outcome key
    om-0001
    arm key
    OG000
    arm label
    Treatment (Paclitaxel)
    regimen
    Patients receive paclitaxel IV over 3 hours on day 1. Treatment continues every 21 days in the absence of disease progression or unacceptable toxicity. Paclitaxel: Given IV
    analyzed count
    31
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00006227-om-0001#groups/OG000
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-ovarian-neoplasm
    nct id
    NCT00006227
    outcome key
    om-0002
    arm key
    OG000
    arm label
    Treatment (Paclitaxel)
    regimen
    Patients receive paclitaxel IV over 3 hours on day 1. Treatment continues every 21 days in the absence of disease progression or unacceptable toxicity. Paclitaxel: Given IV
    analyzed count
    31
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00006227-om-0002#groups/OG000
harms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-ovarian-neoplasm
    nct id
    NCT00006227
    harm key
    EG000
    source section id
    NCT00006227-ae
    event group key
    EG000
    event group label
    Treatment (Paclitaxel)
    serious affected
    1
    serious at risk
    31
    other affected
    31
    other at risk
    31
    frequency threshold
    5
    collection period
    For the duration of treatment and follow-up
    event definition
    Adverse events were defined according to CTC v2.0 for the period of protocol activation through March 31, 2010. Beginning on April 1, 2010 adverse events were defined according to CTCAE v4.0.
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
quality of life
    setting source links

      Preserved source evidence · Not medical advice